BACKGROUND AND AIM: Transmission of hepatitis B virus (HBV) infection occurs in up to 87.5% of HBsAg-negative recipients of anti-HBc-positive donor livers in the absence of HBV prophylaxis. There is no standardized prophylactic regimen to prevent HBV infection in this setting. The aim of this study was to determine the long-term efficacy of nucleoside analogue to prevent HBV infection in this setting. METHODS: A retrospective study of HBsAg-negative patients receiving liver transplantation (LT) from anti-HBc-positive donors during a 10-year period. RESULTS: Twenty patients were studied, mean age was 50.2 ± 8.3 years, 40% were men, and 90% were Caucasian. The median MELD score at the time of LT was 18 (12-40). None of the patients received hepatitis B immune globulin. Eighteen patients received nucleoside analogue monotherapy: 10 received lamivudine and 8 received entecavir. None of these 18 patients developed HBV infection after a median follow up of 32 (1-75) months. One patient received a second course of hepatitis B vaccine 50 months after LT with anti-HBs titer above 1,000 mIU/mL. Lamivudine was discontinued and the patient remained HBsAg negative 18 months after withdrawal of lamivudine. Two patients who were anti-HBs positive before LT were not started on HBV prophylaxis after LT; both developed HBV infection after LT. CONCLUSIONS: Nucleoside monotherapy is sufficient in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. HBV prophylaxis is necessary in anti-HBs-positive recipients of anti-HBc-positive donor livers.
BACKGROUND AND AIM: Transmission of hepatitis B virus (HBV) infection occurs in up to 87.5% of HBsAg-negative recipients of anti-HBc-positive donor livers in the absence of HBV prophylaxis. There is no standardized prophylactic regimen to prevent HBV infection in this setting. The aim of this study was to determine the long-term efficacy of nucleoside analogue to prevent HBV infection in this setting. METHODS: A retrospective study of HBsAg-negative patients receiving liver transplantation (LT) from anti-HBc-positive donors during a 10-year period. RESULTS: Twenty patients were studied, mean age was 50.2 ± 8.3 years, 40% were men, and 90% were Caucasian. The median MELD score at the time of LT was 18 (12-40). None of the patients received hepatitis B immune globulin. Eighteen patients received nucleoside analogue monotherapy: 10 received lamivudine and 8 received entecavir. None of these 18 patients developed HBV infection after a median follow up of 32 (1-75) months. One patient received a second course of hepatitis B vaccine 50 months after LT with anti-HBs titer above 1,000 mIU/mL. Lamivudine was discontinued and the patient remained HBsAg negative 18 months after withdrawal of lamivudine. Two patients who were anti-HBs positive before LT were not started on HBV prophylaxis after LT; both developed HBV infection after LT. CONCLUSIONS:Nucleoside monotherapy is sufficient in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. HBV prophylaxis is necessary in anti-HBs-positive recipients of anti-HBc-positive donor livers.
Authors: J R Nery; R Gedaly; R Vianna; M Berho; D Weppler; D Levi; T Kato; F Khan; A Pinna; E Schiff; A Tzakis Journal: Transplant Proc Date: 2001 Feb-Mar Impact factor: 1.066
Authors: M Prieto; M D Gómez; M Berenguer; J Córdoba; J M Rayón; M Pastor; A García-Herola; D Nicolás; D Carrasco; J F Orbis; J Mir; J Berenguer Journal: Liver Transpl Date: 2001-01 Impact factor: 5.799
Authors: Cosme Manzarbeitia; David J Reich; Jorge A Ortiz; Kenneth D Rothstein; Victor R Araya; Santiago J Munoz Journal: Liver Transpl Date: 2002-06 Impact factor: 5.799
Authors: R C Dickson; J E Everhart; J R Lake; Y Wei; E C Seaberg; R H Wiesner; R K Zetterman; T L Pruett; M B Ishitani; J H Hoofnagle Journal: Gastroenterology Date: 1997-11 Impact factor: 22.682
Authors: Jens Rosenau; Nazanin Hooman; Johannes Hadem; Kinan Rifai; Matthias J Bahr; Gunnar Philipp; Hans L Tillmann; Juergen Klempnauer; Christian P Strassburg; Michael P Manns Journal: Liver Transpl Date: 2007-03 Impact factor: 5.799
Authors: Christian M Lange; Jörg Bojunga; Wolf Peter Hofmann; Katrin Wunder; Ulrike Mihm; Stefan Zeuzem; Christoph Sarrazin Journal: Hepatology Date: 2009-12 Impact factor: 17.425